We performed a multicentre, phase IV, open-label clinical trial to examine the clinical usefulness of a continuous infusion of nicardipine hydrochloride to control hypertension in 31 patients with acute aortic dissection. Target blood pressure levels were reached within 15 min in 16 patients; in 15 -30 min in 10 patients; in 30 -45 min in three patients; and in 45 -60 min in two patients. Baseline average systolic, diastolic and mean arterial blood pressures were 147 ± 23 mmHg, 82 ± 18 mmHg and 104 ± 18 mmHg, respectively, with third-day pressures significantly reduced at 119 ± 12 mmHg, 69 ± 9 mmHg and 86 ± 8 mmHg. Blood pressures after discontinuation of the infusion were not significantly different from those measured on the third day of infusion and no definite adverse effects attributable to the treatment were observed. Nicardipine hydrochloride was both effective and safe at controlling blood pressure in patients with acute aortic dissection.
Introduction
A hypertensive emergency is defined as a state in which both the systolic and diastolic blood pressures are elevated in combination with acute or ongoing target organ disease. This state requires a prompt reduction of blood pressure by use of parenteral antihypertensive drugs and continuous monitoring of arterial pressure. Hypertensive emergencies include hypertensive encephalopathy, acute left ventricular failure, eclampsia, acute aortic dissection, hypertension after coronary artery bypass grafting, and hypertension associated with circulating catecholamines.
Aortic dissection is characterized by the separation of layers of the aortic media by a column of circulating blood with variable proximal and distal extension throughout the entire length of the aorta. The majority of intimal tears are located within the first few centimetres of the ascending aorta; the second most common site is the initial portion of the descending aorta. The natural course of acute aortic dissection has a very poor prognosis: 38% of patients die within 24 h, 70% within 1 week and 92% within 1 month. 1 Because arterial hypertension is the most important predisposing factor for aortic dissection, prompt anti-hypertensive therapy and maintenance of a systolic blood pressure of < 120 mmHg is mandatory. Pharmacotherapy is the treatment of choice in acute dissection confined to the descending aorta, whereas dissection involving the ascending aorta requires surgical intervention. The treatment goals of anti-hypertensive therapy in acute aortic dissection are the prevention of both the propagation of the dissection and early thrombus formation within the false lumen. The preferred method of antihypertensive therapy is the continuous infusion of parenteral anti-hypertensive drugs.
Intravenous nicardipine hydrochloride (Perdipine ® , Yamanouchi Pharmaceutical Company, Tokyo, Japan) is a parenteral antihypertensive agent currently used worldwide for peri-operative hypertension and hypertensive emergency. It is suggested that this drug may be effective in the treatment of acute aortic dissection. The onset of the antihypertensive effect of nicardipine is known to be approximately 5 -10 min after administration, and its duration of action is approximately 2 h. Nicardipine exerts its anti-hypertensive effect by decreasing peripheral vascular resistance and thereby reducing afterload. It has no negative inotropic effect and does not decrease cardiac output. Furthermore, compared with nitrates, nicardipine has minimal effect on heart rate and can maintain stable blood pressure. Moreover, its photostable and hydrophilic chemical structure make nicardipine appropriate for intravenous usage.
We undertook a multicentre phase IV clinical trial to examine the clinical usefulness of a continuous infusion of nicardipine hydrochloride to control hypertension in patients with acute aortic dissection.
Patients and methods
The aim of this study was to examine the clinical efficacy and safety of a continuous infusion of nicardipine hydrochloride as a parenteral anti-hypertensive agent in patients with acute aortic dissection or other aortic diseases. The period of nicardipine administration was limited to between 3 days and 14 days, and administration by infusion was discontinued when oral intake was possible.
A total of 31 patients with diagnoses of acute aortic dissection, ruptured aortic arch aneurysm or traumatic aortic rupture were recruited to the study. All gave their informed consent to participate in the trial.
DRUG ADMINISTRATION
The generic name of the test drug is nicardipine hydrochloride. It is a clear, lightyellow liquid prepared in an ampoule. One millilitre of the preparation contains 1 mg nicardipine hydrochloride and 50 mg D-sorbitol, buffered with hydrogen chloride and dissolved in sterile water for injection. Qualified pharmacists were charged with managing the drugs for this clinical trial, recording the amount of the drug received and used, and confirming that the drug was being used according to the clinical trial protocol. Patients excluded from the study included those with the following characteristics: (i) a state of shock; (ii) severe arrhythmia; (iii) atrial fibrillation; (iv) a history of hypersensitivity to nicardipine; and (v) those, in the opinion of the participating physician, regarded as inappropriate for the study for any other medical reason.
METHOD OF TEST DRUG ADMINISTRATION
The test drug was administered either diluted or undiluted at the discretion of the consulting physician according to patient requirements. In either case, the target blood pressure level was defined as a systolic blood pressure of 120 -140 mmHg.
Administration of the diluted solution
Three ampoules (30 mg) of the test drug were diluted in 250 ml of 5% dextrose solution or normal saline. This solution was infused continuously via an intravenous catheter at an initial rate of 20 ml/h (approximately 2 mg/h). The infusion rate was adjusted until the arterial pressure reached the target level within 30 -60 min. After the target level had been reached, the rate of infusion was adjusted to maintain this level of arterial pressure. The upper limit of the infusion rate was 300 ml/h (approximately 30 mg/h or 6 µg/kg per min).
Administration of the undiluted drug
The undiluted drug was infused continuously via a central venous catheter at an initial rate of 2 ml/h (2 mg/h). The infusion rate was adjusted until the pressure reached a target level within 30 -60 min. After the target level had been reached, the rate of infusion was adjusted to maintain this level of arterial pressure. The upper limit of the infusion rate was 30 ml/h (approximately 30 mg/h or 6 µg/kg per min). Infusion through a peripheral venous line was prohibited because of the possibility of phlebitis due to the high acidity of the undiluted drug.
CONCOMITANT USE OF OTHER ANTI-HYPERTENSIVE AGENTS
Oral anti-hypertensive agents other than β-blockers (e.g. α-blockers, calcium antagonists, angiotensin-converting enzyme inhibitors and angiotensin II antagonists) were not administered concomitantly with intravenous nicardipine. Any patients who had been taking these drugs before the study were allowed to resume taking these drugs after study completion. Patients taking β-blockers, such as propranolol, were allowed to take them simultaneously with nicardipine. It is known that the concomitant administration of β-blockers with a parenteral antihypertensive agent is desirable because of possible tachycardia resulting from the abrupt reduction of blood pressure induced by the anti-hypertensive agent. This is particularly true for patients with acute aortic dissection.
Other intravenous anti-hypertensive agents (nitroglycerin, diltiazem, verapamil, nitroprusside and hydralazine) were not allowed for use simultaneously. However, since acute aortic dissection is a hypertensive emergency, which requires a prompt reduction of blood pressure within 1 -2 h, concomitant use of other intravenous agents was allowed if nicardipine did not produce a satisfactory anti-hypertensive effect even at the maximal dosage. In this case, the identity, administration dose and duration of administration were recorded.
ASSESSMENT OF THE EFFICACY OF NICARDIPINE
Efficacy assessment was undertaken by evaluating major and minor endpoints. The major endpoint was the average amount of blood pressure reduction on the third day after the start of the test drug infusion (average of the differences between the baseline pressure and pressure on the third day). The minor endpoints were: (i) Mean blood pressure reduction at the end of the study: average of the differences between baseline pressure Clinical trial of nicardipine for acute aortic dissection and pressure at the end of the study; (ii) Degree of reduction in blood pressure: percentage of patients whose blood pressure was regarded as 'reduced' according to the criteria in Table 1 ; (iii) Blood pressure normalization ratio:
percentage of patients whose blood pressure was normalized (< 140/90 mmHg) on the third day and at the end of the study; (iv) Target pressure achievement ratio:
percentage of patients whose blood pressure reached the target pressure (a systolic blood pressure of 100 -120 mmHg) at the third day and at the end of the study; (v) Changes in signs and symptoms during the study period.
MONITORING PROCEDURE
Arterial blood pressure (systolic, diastolic and mean) and heart rate were recorded before the nicardipine infusion. These values were recorded every 15 min up to 60 min after the start of the infusion; every 30 min up to 2 h; every 2 h up to 8 h; every 4 h up to 24 h; and every 8 h thereafter. The infusion rate at the time of monitoring was also recorded. Symptoms and signs associated with aortic disease, such as pain, heart failure and consciousness level, were also recorded at the aforementioned points. Continuous electrocardiographic monitoring was performed before and throughout the infusion period. Laboratory examination included blood count (red blood cell, white blood cell, haemoglobin, haematocrit, platelet), blood chemistry (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase, lactate dehydrogenase, total cholesterol, thromboplastin generation, protein, blood urea nitrogen, creatinine, sodium, chloride and potassium) and urinalysis (protein, glucose, urobilinogen). These tests were performed before the start of the nicardipine infusion, as a baseline, and after the discontinuation of the nicardipine infusion.
ASSESSMENT OF ADVERSE EFFECTS
An adverse effect was defined as any newly developed symptom or worsening of any pre-existing complication irrespective of its association with the test drug during the course of the study. The type, duration, severity, management, course and association of any such event with the test drug were examined and recorded.
STATISTICAL ANALYSIS Average amount of blood pressure reduction
For each patient, the difference between the baseline blood pressure and the pressure at the third day was obtained. The average of the differences was obtained and a paired Student's t-test was used to evaluate the significance. The same was done for the average of the differences between the 
Degree of blood pressure reduction
The difference between the baseline blood pressure and the pressure at the third day was obtained for each patient. One of the four categories in Table 1 was assigned to this difference. The same was done for the differences between the baseline pressure and the pressure at the end of the study. If the assignment according to the systolic blood pressure and the assignment according to the diastolic blood pressure were not the same, the assignment according to the mean blood pressure was used. Even if the difference did not meet the criteria of 'reduced', it was regarded as reduced if it met the criteria of 'reducing tendency', and the blood pressure was < 140/90 mmHg.
Blood pressure reduction ratio
This was defined as the percentage of patients whose blood pressure was regarded as reduced according to the criteria described in Table 1 . The percentage of patients who received another anti-hypertensive agent simultaneously, among the patients whose blood pressure was regarded as reduced, was calculated to examine the anti-hypertensive effect of the concomitantly used agent.
Blood pressure normalization ratio
The percentage of patients whose blood pressure was normalized (< 140/90 mmHg) on the third day and at the end of the study was recorded. The percentage of patients who received another anti-hypertensive agent simultaneously, among the patients whose blood pressure was normalized, was calculated to examine the anti-hypertensive effect of the concomitantly used agent.
Target pressure achievement ratio
The percentage of patients whose blood pressure reached the target pressure (a systolic pressure of 100 -120 mmHg) on the third day and at the end of the study was recorded. The percentage of patients who received another anti-hypertensive agent simultaneously, among the patients whose blood pressure reached the target level, was calculated to examine the anti-hypertensive effect of the concomitantly used agent.
Results
A total of 31 patients were enrolled in the study. All patients were diagnosed using pre-operative computed tomography (CT). Their diagnoses are summarized in Table 2 . Their mean age was 53.9 ± 14.9 years (range, 29 -89 years). One patient was 29, six were in their 30s, five were in their 40s, six were in their 50s, 10 were in their 60s, two in their 70s and one was 89. Twenty-one (68%) were men and 10 (32%) were women. Patients diagnosed with acute aortic dissection were classified according to both the Stanford and DeBakey classifications ( Table 2) . 1 Complications resulting from underlying aortic disease at the time of the diagnosis were observed in 14 patients (45%; Table 3 ). Patient history revealed the following prior surgical interventions: surgery for acute aortic dissection in two; replacement of the aorta for abdominal aortic aneurysm in one; aortic valve replacement in one; and bypass surgery for atherosclerotic peripheral arterial occlusive disease in one. Of all the patients recruited to the study, 24 had a history of hypertension and seven did not, although they were hypertensive at the time of their admission. One patient had pregnancyinduced hypertension associated with pre-eclampsia and one patient had Marfan syndrome. Fourteen patients had surgery for At the time of their admission, 15 patients were receiving treatment with parenteral anti-hypertensive drugs. Sodium nitroprusside was used in eight patients, simultaneous sodium nitroprusside and β-blockers (esmolol or labetalol) were used in two, β-blockers in four, and nifedipine in one.
Continuous infusion of nicardipine was
started in all patients. The infusion rate of nicardipine was increased as the infusion rate of the other anti-hypertensive agents was decreased slowly until the discontinuation of that specific agent.
The average time needed to reach the target blood pressure level was 25.6 ± 13.5 (15 -60) min and the average infusion rate of nicardipine during this period was 2.1 ± 3.1 (0.3 -15) mg/h. The time needed to reach the target blood pressure level was < 15 min in 16 patients; 15 -30 min in 10; 30 -45 min in three; and 45 -60 min in two. The extent of aortic dissection progressed in two patients, remained unchanged in 23, and in 6 patients, it was not possible to repeat the CT scan to assess disease progress. In no cases did the aortic dissection progress to rupture.
Baseline average systolic, diastolic and mean arterial blood pressures were 147 ± 23 mmHg, 82 ± 18 mmHg and 104 ± 18 mmHg, respectively. The average systolic, diastolic and mean arterial blood pressures on the third day after the start of the nicardipine infusion were 119 ± 12 mmHg, 69 ± 9 mmHg and 86 ± 8 mmHg, respectively. A significant reduction in blood pressure was obtained on the third day versus the baseline blood pressures (P < 0.05). The average systolic, diastolic and mean arterial blood pressures after the discontinuation of the nicardipine infusion were 119 ± 15 mmHg, 71 ± 14 mmHg and 86 ± 13 mmHg, respectively. There was no significant difference between the average pressures measured on the third day and those measured after the discontinuation of the nicardipine infusion.
Diastolic and mean arterial blood pressures of the patients with aortic insufficiency were excluded from the analysis because of their low baseline diastolic pressures. The courses of arterial blood pressures and heart rate from day 1 to day 7 after the start of the nicardipine infusion are shown in Fig. 1 . The systolic and diastolic blood pressures decreased significantly within 30 min and were maintained thereafter (P < 0.05). Nicardipine infusion did not have a significant influence on heart rate.
No definite adverse events occurred during administration of the nicardipine infusion.
Elevated serum AST/ALT levels were observed in one patient, but these improved after surgery. Decreased urine output, elevated serum creatinine level, changes in electrocardiogram and tachycardia were observed, but all of these findings were thought to be associated with pre-existing complications or the progress of the aortic dissection.
Discussion
Acute aortic dissection associated with hypertension is a state of medicosurgical emergency, which requires urgent initial pharmacotherapy to lower the arterial blood pressure. An acute increase in peripheral vascular resistance is considered to be the predominant physiological pathway for therapeutic purposes in acute hypertensive crises. 2 Various anti-hypertensive agents can be used in acute aortic dissection. The ideal properties of intravenous agents for use in acute hypertension include the ability to regulate easily blood pressure responses in individual patients, allow the control of blood pressure reduction, and minimize the risk of hypotension. Treatment preparation should be rapid and simple, and the agent should have minimal side-effects.
Sodium nitroprusside, a potent and shortacting vasodilator, is one of the most widely Blood pressure (mmHg)/ heart rate (beats per min) Nicardipine infusion (mg/h) Clinical trial of nicardipine for acute aortic dissection used parenteral anti-hypertensive drugs in patients with acute aortic dissection. Despite its effectiveness and its rapid onset of action in lowering blood pressure, it has some disadvantages. Specifically, it could be responsible for impairing the myocardial oxygen balance because of an excessive decrease in diastolic blood pressure, reflex tachycardia and coronary steal phenomenon, particularly in patients with coronary artery disease. 3 -7 Sodium nitroprusside is photosensitive and requires time-consuming foil wrapping of the administration set to safeguard its potency. Furthermore, nitroprusside is toxic when administered at elevated doses.
Acute arteriolar vasoconstriction is considered to be the common physiological pathway for hypertensive crises. 8 In the vascular tree, calcium is the key messenger that translates the physiological commands for increased blood pressure into the actual contraction of the vascular smooth muscle cells, 9, 10 and calcium channel blockers are commonly used as vasodilators for treatment of hypertensive crises. Nicardipine hydrochloride, a dihydropyridine calcium channel blocker, is a vasoselective agent with minimal negative inotropic effects. 11 It is photostable and water-soluble, and can be administered intravenously. 11 It is not only a potent arterial vasodilator, but also produces a favourable effect on the coronary circulation 12 and is devoid of systemic toxicity. 13 Intravenous nicardipine has proven to be an effective anti-hypertensive treatment in cases of moderate-to-severe hypertension, 14 and is as effective as sodium nitroprusside for the immediate control of blood pressure in patients with severe hypertension. 15 It has also proven to be as effective as nitroprusside for the control of hypertension after coronary artery bypass grafting. 16 We performed a clinical trial to examine the efficacy and safety of nicardipine infusion in patients with acute aortic dissection and other aortic diseases. The majority of patients showed a rapid reduction of blood pressure after nicardipine infusion, and maintenance of this reduced blood pressure level was stable. Neither reflex tachycardia nor excessive reduction of diastolic pressure was observed, and no adverse effects were observed that were believed to be directly associated with the nicardipine infusion.
Nicardipine hydrochloride is both effective and well tolerated for controlling blood pressure in patients with acute aortic dissection. A comparative study with other anti-hypertensive agents, such as nitroprusside, may be needed.
